Presidential Proclamation Imposes Tariffs to Secure Domestic Pharmaceutical Production
Impact Score: 3.6
Timeline: Tariffs effective July 31, 2026 and September 29, 2026; ongoing negotiations with 90-day progress updates; tariff adjustments through 2030
Summary: To address national security risks from heavy reliance on imported patented pharmaceuticals and active pharmaceutical ingredients (APIs), the President ordered tariffs up to 100% on imports, with reduced rates for approved onshoring plans and certain trade partners. Exemptions apply to generics and U.S.-origin products. Negotiations with trade partners and pharmaceutical companies on onshoring and pricing commitments are mandated, with key federal agencies overseeing implementation. The declaration aims to strengthen domestic pharmaceutical manufacturing, ensuring supply chain security amid vulnerabilities exposed by foreign dependence.
Key Actions: Vanderbilt should monitor tariff and onshoring impacts on research and supply chains, develop contingency plans for drug sourcing, engage pharmaceutical partners for onshoring collaboration, assess federal funding changes, and explore research opportunities linked to domestic production initiatives.
View Full Report
